Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05101928
Other study ID # CRRF ID 3008
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 30, 2021
Est. completion date September 30, 2027

Study information

Verified date April 2024
Source Ottawa Hospital Research Institute
Contact Miriam Muir, RN
Phone 613-737-8519
Email mmuir@ohri.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of non-infectious intermediate-, posterior- or panuveitis. This is a prospective randomized controlled clinical trial taking place at the University of Ottawa Eye Institute, Ottawa, Ontario, Canada, and other possible centers in Canada. Consecutive consenting subjects who meet inclusion/exclusion criteria will be selected to participate in this study. The subjects must have either non-infectious intermediate, posterior, or panuveitis. The subjects will be randomly chosen to be part of one of two groups; one group will receive DEX as monotherapy and the other group will receive oral prednisone. Approximately 84 eyes (42 per arm) will take part in study. The primary outcome will measure the proportion of eyes with a vitreous haze score of 0 six months post initial treatment. Secondary measures will include best corrected visual acuity (BCVA), central retinal thickness (CRT) measured by spectral-domain optical coherence tomography (SD-OCT), time to vitreous haze resolution and time to failure defined at number of months with DEX implant until an adjunct therapy is indicated. Baseline measurements will be recorded within 1 month prior to treatment in both groups, with follow up measurements collected at 0, 1, 2, 4, 6 and 12 months post-operatively.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date September 30, 2027
Est. primary completion date September 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Diagnosis of non-infectious intermediate, posterior, or panuveitis in at least one eye - Active uveitic disease at Screening/Baseline defined by the presence of at least 1 of the following parameters: 1) Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion 2) = 1+ vitreous haze (NEI/SUN criteria) Exclusion Criteria: - Presence of isolated anterior uveitis - Evidence of macular edema due to diabetes, retinal vein occlusion or any other ocular conditions - Confirmed or suspected active ocular disease or infections - Intraocular surgery in the past 6 months - History of glaucoma - Intraocular pressure (IOP) of >21 mmHg at Screening/Baseline or confirmed normal-tension glaucoma - Intravitreal or periocular injection within 6 months prior to screening. - Unable to tolerate systemic corticosteroids - Prior topical corticosteroid within 1 month of screening - Prior non-steroidal anti-inflammatory, systemic steroids, or immunomodulatory therapy (e.g. methotrexate) within 1 month of screening - For women: pregnant or breast feeding, or planning to become pregnant while enrolled in the study

Study Design


Intervention

Drug:
Ozurdex 0.7mg Ophthalmic Implant
A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
Prednisone
The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.

Locations

Country Name City State
Canada Ottawa Hospital Research Institute - Vision Research Centre Ottawa Ontario

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with Vitreous Haze score of 0 at 6 months This score (using NEI/SUN criteria) is used to grade intraocular inflammation based on vitreous cells and protein exudation. A lower score is indicative of less inflammation which is the goal when using either Ozurdex implant or a oral prednisone. Measurements obtained at 6 months
Secondary Best Corrected Visual Acuity at various time points This score will be used to determine the functional outcome (visual acuity) with the treatments. Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months
Secondary Proportion of patients with vitreous haze improvement by 1, and 2 units from baseline to various time points This score will be used to look at the degree of changes in the inflammation. Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months
Secondary Time to vitreous haze score of 0 from baseline to various time points This will be used to assess if there are differences in time to achieving lowest possible inflammation amongst groups. Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months
Secondary Anterior chamber cells/flare from baseline to various time points Using SUN grading criteria, the proportion of patients with cells grade 0, 0.5+, 1+, 2+, 3+, 4+ and flare grade of 0, 1+, 2+, 3+, 4+ will be determined at Month 6. Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months
Secondary Change in central average thickness (µm) from baseline to various time points This score will be used to assess anatomical changes (e.g. cystoid macular edema) with treatment Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months
Secondary Change in central average volume (in mm3) from baseline to various time points This score will be used to assess anatomical changes (e.g. cystoid macular edema) with treatment Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months
Secondary Change in National Eye Institute Visual Function Questionnaire 25 Score This will be used to determine impact of disease on the subject's quality of life. The worst possible score is 0 while best is 100. The higher the score, the higher the subjective visual function. Baseline and 12mo
Secondary Incidence of complications Measure complication of treatment including but not limited to cataracts formation, ocular hypertension, vitreous hemorrhage, and endophthalmitis. Anywhere between baseline to 12 months
Secondary Percentage of patients with Vitreous Haze score of 0 at various time points This score (using NEI/SUN criteria) is used to grade intraocular inflammation based on vitreous cells and protein exudation. A lower score is indicative of less inflammation which is the goal when using either Ozurdex implant or a oral prednisone. Measurements obtained at: 1 month, 2 months, 4 months, 6 months (primary outcome), 12 months
See also
  Status Clinical Trial Phase
Completed NCT00570479 - Prophylactic Anecortave Acetate in Patients With a Retisert Implant Phase 1
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Terminated NCT03656692 - Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) Phase 4
Completed NCT02255032 - Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Phase 2
Completed NCT00035906 - Research Study in Patients With Persistent Macular Edema Phase 2
Terminated NCT05070728 - Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) Phase 3
Completed NCT02595398 - Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Phase 3
Recruiting NCT03066869 - Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Phase 4
Completed NCT01539577 - A Long-Term Safety Study of OZURDEX® in Clinical Practice N/A
Recruiting NCT05322070 - Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis Phase 4
Recruiting NCT06085079 - Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study Phase 4
Completed NCT03145025 - Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Withdrawn NCT01905124 - Safety &Efficacy of CF101 to Subjects With Uveitis Phase 2
Completed NCT02049476 - Study of the Effectiveness of Ozurdex for the Control of Uveitis Phase 4
Completed NCT03598452 - High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients N/A
Completed NCT00404742 - A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Phase 3
Completed NCT00404612 - A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Phase 3
Completed NCT02952001 - MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Not yet recruiting NCT06431373 - A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Phase 3
Completed NCT03097315 - Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Phase 3